WO2011070369A1 - Inhibiteurs de kinase de cellules hémopoïétiques (p59-hck) et leur utilisation dans le traitement d'une infection par le virus de la grippe - Google Patents

Inhibiteurs de kinase de cellules hémopoïétiques (p59-hck) et leur utilisation dans le traitement d'une infection par le virus de la grippe Download PDF

Info

Publication number
WO2011070369A1
WO2011070369A1 PCT/GB2010/052067 GB2010052067W WO2011070369A1 WO 2011070369 A1 WO2011070369 A1 WO 2011070369A1 GB 2010052067 W GB2010052067 W GB 2010052067W WO 2011070369 A1 WO2011070369 A1 WO 2011070369A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
butyl
pyridin
compound
pyrazol
Prior art date
Application number
PCT/GB2010/052067
Other languages
English (en)
Inventor
Catherine Elisabeth Charron
Robert Fenton
Scott Crowe
Kazuhiro Ito
Peter Strong
Garth Rapeport
Keith Ray
Original Assignee
Respivert Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Limited filed Critical Respivert Limited
Priority to US13/514,644 priority Critical patent/US20120244120A1/en
Priority to CN201080063651.5A priority patent/CN102762204B/zh
Priority to AU2010329645A priority patent/AU2010329645B2/en
Priority to JP2012542622A priority patent/JP2013513596A/ja
Priority to EP10788125.2A priority patent/EP2509595B1/fr
Publication of WO2011070369A1 publication Critical patent/WO2011070369A1/fr
Priority to US14/883,464 priority patent/US20160045512A1/en
Priority to US15/706,152 priority patent/US20180000830A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the present application relates to the use of compounds capable of inhibiting p59-HCK activity in the treatment and/or prophylaxis of infection with influenza virus.
  • the compounds may be administered as a monotherapy or in combination with other anti-viral agents, either concomitantly or sequentially.
  • Seasonal influenza is a sub-acute illness caused by infection with influenza virus (A, B or C strains) and is usually characterised by a sudden rise in temperature and general aches and pains and may include appetite loss and cough. Seasonal influenza causes significant mortality in well defined sub-sets of the population, in particular the very young, the elderly and those suffering from chronic diseases, such as congestive heart failure, being most at risk. In the United States of America, 30,000-40,000 people are estimated to die as a result of infection with influenza virus each year. Public health policy recognises that environmental conditions are an important additional factor when assessing risk. For example, living in a residential or nursing home is considered an additional risk during outbreaks of seasonal influenza since the probability of contact with infection can be significantly elevated. In addition to an increased risk of death, infection with the influenza virus produces significant morbidity in the wider population (Nichol K.L. et al., N. Engl. J. Med., 1995, 333:889-93).
  • Seasonal influenza usually follows an epidemic pattern of infection, affecting many people at once within a defined geographic region. Although the virus affects all age groups, the highest incidence of infection usually occurs in school children.
  • the public health impact of seasonal influenza is limited by the presence of immunity in the population and widespread vaccination. Influenza disease may also follow a pandemic pattern of infection when a new influenza virus emerges for which the global population has little or no immunity and for which there is no effective vaccine that is available to be deployed rapidly.
  • the public health impact of a pandemic depends on the properties of the influenza virus that is responsible. In the case of the "Spanish 'flu" (1918-1920), the pattern of mortality was uncharacteristic of influenza.
  • vaccination does not provide effective protection in a percentage of the general population and it is not suitable for immuno-suppressed groups, such as cancer patients undergoing chemotherapy.
  • these products are traditionally produced by incubation in eggs, they are not suitable for administration to individuals who have an allergy to eggs.
  • the time course between vaccination and effective protection can be somewhat extended, leaving a time window when individuals remain vulnerable to infection in the period between the vaccine being administered and the immune system's response being complete.
  • a new vaccine has to be produced for each new influenza virus which emerges as a cause of influenza disease. While the relatively predictable pattern of spread of seasonal influenza allows timely production of a new vaccine, the rapid spread of pandemic influenza across a wider geographic area is more challenging in this regard.
  • the commonest form of vaccination involves intra-muscular injection of a product containing inactivated virus having the phenotype of the influenza virus that is currently circulating.
  • a new mist vaccine, FluMist was first approved in 2003 and is indicated for patients between the age of 5 and 49.
  • the vaccine is sprayed into the nose and works in a manner similar to injectable products.
  • This vaccine includes live influenza virus, so it cannot be given to persons with weak immune systems or pregnant women.
  • combination therapy can be a highly effective approach in the treatment of infectious diseases and is particularly effective as a strategy to minimise the risk of resistant strains arising from treatment.
  • This is well illustrated by the evolution of drug treatments for HIV infection, which began as monotherapy but developed steadily to the point where triple therapy, using drugs directed against two distinct viral proteins, is regarded as the gold standard.
  • an anti-influenza combination incorporating oseltamivir, amantadine, and ribavirin, displayed synergistic activity against multiple influenza virus strains in vitro (Nguyen J.T., et al., Antimicrob. Agents Chemother., 2009, 53:41 15-4126).
  • the present application relates to the identification for the first time of the role of hemopoietic cell kinase (p59-HCK) in influenza virus infection.
  • p59-HCK is a little studied kinase which is a member of the Src B family of enzymes. It has only been previously described as being involved in linking activation of the Fc receptor to activation of the respiratory burst in neutrophils and macrophages (Guiet R., Poincloux R. et al., Eur. J. Cell Biol., 2008, 87:527-42). Surprisingly, it has been found that compounds that inhibit p59-HCK also result in a decrease in influenza virus load in both in vitro and in vivo models.
  • the present invention provides for the use of compounds which inhibit the activity of p59-HCK in the manufacture of a medicament to treat or prevent (i.e. prophylaxis of) infection by influenza virus (A, B and C strains including subtypes influenza A virus, influenza B virus, avian strain H5N1 , A/H1 N 1 , H3N2 and/or pandemic influenza).
  • influenza virus A, B and C strains including subtypes influenza A virus, influenza B virus, avian strain H5N1 , A/H1 N 1 , H3N2 and/or pandemic influenza.
  • the present invention also provides a compound capable of inhibiting hemopoietic cell kinase (p59-HCK) activity for use in the treatment or prophylaxis of infection by influenza virus (A, B and C strains including subtypes influenza A virus, influenza B virus, avian strain H5N1 , A/H1 N 1 , H3N2 and/or pandemic influenza), a method of treating or preventing infection by influenza virus (A, B and C strains including subtypes influenza A virus, influenza B virus, avian strain H5N1 , A H1 N1 , H3N2 and/or pandemic influenza) comprising administering to a patient a therapeutically effective amount of a compound capable of inhibiting p59-HCK activity in a patient.
  • p59-HCK hemopoietic cell kinase
  • the compounds capable of inhibiting the activity of p59-HCK may either act directly on the p59-HCK enzyme, act to reduce the activity of p59-HCK enzyme present, by, for example, decreasing the level of the enzyme or decreasing the activity of the enzyme present, or may act to reduce the availability of the substrates of p59-HCK enzyme.
  • the compound is a chemical inhibitor (e.g. a small molecule with for instance a molecular weight of less than 1500, less than 1000 or less than 750 Daltons) of p59- HCK activity.
  • the chemical inhibitor may be a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the chemical inhibitor is not a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the chemical inhibitor is not /V-(4-(4-(3-(3-ie f-butyl-1 -p-tolyl-1 /-/-pyrazol-5-yl) ureido)naphthalen-1 -yloxy)pyridin-2-yl)-2-methoxyacetamide or a pharmaceutically acceptable salt or solvate thereof.
  • the compound is a biochemical inhibitor of p59-HCK activity.
  • the compound may be a RNAi molecule or microRNA (miRNA) molecule that suppresses the expression of p59-HCK.
  • the RNAi molecules may be antisense oligonucleotides, small interfering RNA (siRNA) molecules.
  • Antisense oligonucleotides are short single stranded oligonucleotides in the region of 16 bases in length which act by employing the naturally occurring, intracellular enzyme RNase H to cleave and degrade the mRNA.
  • siRNAs are double-stranded oligonucleotides in the region of 19 base pairs in length which act by employing the naturally occurring, intracellular mechanism of the RNA-induced silencing complex (RISC).
  • RISC RNA-induced silencing complex
  • MicroRNA molecules are evolutionary conserved, small (20-24 bases), non-coding molecules that regulate gene expression at the level of translation in humans.
  • the RNAi molecules may be modified to improve their stability and potency through the incorporation of a modified backbone, incorporating for instance 2'deoxynucleotide phosphothioate, 2'deoxynucleotide methylphosponate or peptide nucleic acids.
  • RNAi molecules and miRNA may be delivered as aptomer conjugated siRNA, by incorporation into lipid nanoparticles, which may optionally be targeted to specific cells, as dynamic polyconjugates, by incorporation into cyclodextrin nanoparticles, as lipophihilic conjugated siRNA, or simply as "naked" RNAi molecules.
  • the compounds suitable for use according to the present invention may act to inhibit the activity of the p59-HCK through competitive inhibition, uncompetitive inhibition, mixed inhibition and/or non-competitive inhibition.
  • the use of the present invention is particularly suited to the treatment or prophylaxis of patients classified as "at-risk patients".
  • at-risk patients include, but are not limited to, pregnant women or patients undergoing chemotherapy.
  • the use of the present invention is suited to the treatment or prophylaxis of patients suffering complications (pulmonary and systemic) arising from infection by influenza virus (A, B and C strains).
  • the use of the present invention is also suited to the treatment or prophylaxis of patients with chronic diseases, such as, but not limited to, diabetes, congestive heart failure, renal failure, chronic obstructive pulmonary disease
  • the compounds capable of inhibiting p59-HCK activity are administered as a monotherapy.
  • the compounds capable of inhibiting p59-HCK activity are administered in combination with one or more anti-viral drugs.
  • suitable anti- viral drugs include, but are not limited to, zanamivir, oseltamivir, laninamivir, peramivir, ribavarin and (exogenous) interferons (including all their physiologically acceptable derivatives such as salts). The use of such combinations allows for more rapid control and/or more rapid resolution of symptoms associated with infection by influenza virus (A, B and C strains) than could be achieved using the anti-viral drug alone.
  • the use of such combinations also allows for the anti- viral drugs to be administered at a lower dose or reduced frequency than is conventionally used in clinical practice when the anti-viral drugs are administered as monotherapies.
  • the dose range for zanamavir when administered in combination with a compound capable of inhibiting p59-HCK activity could be reduced to 0.03 to 3 mg per treatment or preferably 0.3 to 3 mg per treatment.
  • the dosage regime for such combinations may be optimised for the particular compounds to be administered.
  • the anti-viral drugs may be administered simultaneously or sequentially with the compounds capable of inhibiting p59-HCK activity. If the anti-viral drugs and compounds capable of inhibiting p59-HCK activity are administered simultaneously it will also be appreciated that they may be administered in a single formulation or in separate formulations.
  • the compounds capable of inhibiting p59-HCK activity may be administered at a dosage suitable for once per day administration.
  • the administration of the compounds capable of inhibiting p59-HCK activity is via the inhaled route.
  • Such administration may use a metered dose inhaler, a dry powder delivery device, a nasal pump or a nebuliser.
  • the compounds capable of inhibiting p59-HCK activity are administered via the intranasal route or via the oral route.
  • Administration locally to the lung or nose has the advantage that it delivers the drug to a target organ of interest and may typically result in an improved side effect profile by avoiding systemic exposure.
  • novel combination therapeutics comprising a compound capable of inhibiting p59-HCK activity and an anti-viral agent (such as, but not limited to, zanamivir, oseltamivir, laninamivir, peramivir, ribavarin and (exogenous) interferons) are provided.
  • the compound capable of inhibiting p59-HCK activity may be a compound of formula (I).
  • Such combination therapeutics may be provided in particulate form, especially particulate form suitable for inhalation as a dry powder. An example of such a particulate form is one that has a fine particle fraction of at least 50%, but ideally greater than 80%.
  • the combination therapeutics may be suitable for inhalation via a pMDI.
  • Such combination therapeutics may also be provided as solution formulations further comprising a propellant, a solvent and water.
  • a method of screening for substances capable of inhibiting p59- HCK activity is provided, as are p59-HCK inhibitors and their use in therapy.
  • a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection (A, B and C strains) in a subject comprising identifying a test substance capable of inhibiting p59-HCK activity by measuring the effects of said test substance on p59-HCK activity.
  • the method of screening for a candidate drug substance intended to prevent or treat influenza virus infection (A, B and C strains) in a subject comprises the steps of: a. contacting p59-HCK with a test substance in the presence of FRET peptide and ATP;
  • an in vitro method of screening for a candidate drug substance intended to prevent or treat influenza viral infection in a subject which comprises: a. contacting said substance with p59-HCK or cells expressing p59-HCK; and
  • p59-HCK enzymatic activity e.g. phosphorylation of a substrate
  • R 1 is Ci -6 alkyl optionally substituted by a hydroxyl group
  • R 2 is H or Ci-6 alkyl optionally substituted by a hydroxyl group
  • R 3 is H, Ci-6 alkyl or C 0- 3 alkylC 3- 6 cycloalkyl
  • Ar is a naphthyl or a phenyl ring either of which may be optionally substituted by one or more groups (for example 1 to 3, such as 1 , 2 or 3 groups) independently selected from Ci -6 alkyl, Ci_ 6 alkoxy, amino, Ci -4 mono or C 2- 8 di-alkyl amino;
  • L is a saturated or unsaturated branched or unbranched Ci -8 alkylene chain, wherein one or more carbons (for example 1 to 3, such as 1 , 2 or 3 carbons) are optionally replaced by -O- and the chain is optionally substituted by one or more halogen atoms (for example 1 to 6);
  • X is 5 or 6 membered heteroaryl group containing at least one nitrogen atom and optionally including 1 or 2 further heteroatoms selected from O, S and N;
  • Q is selected from:
  • a Co-8 alkyl-heterocycle said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, suitably 1 or 2, in particular 1 heteroatom) selected from O, N, and S, and which is optionally substituted by one, two or three groups independently selected from halogen, hydroxyl, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2-8 di-alkyl amino, Ci -4 mono or C 2-8 di-acyl amino, S(0) q Ci -6 alkyl, C 0- 6 alkylC(0)Ci -6 alkyl, Co-6 alkylC(O)NC 0 -6 alkyl C 0-6 alkyl or C 0-6 alkylC(O)C 0 - 6 heteroalkyl; and
  • p 0, 1 or 2;
  • q 0, 1 or 2;
  • a pharmaceutically acceptable salt thereof including all stereoisomers, tautomers and isotopic derivatives thereof.
  • Alkyl as used herein refers to straight chain or branched chain alkyl, such as, without limitation, methyl, ethyl, n-propyl, /so-propyl, butyl, n-butyl and ie f-butyl. In one embodiment alkyl refers to straight chain alkyl.
  • Alkoxy as used herein refers to straight or branched chain alkoxy, for example methoxy, ethoxy, propoxy, butoxy. Alkoxy as employed herein also extends to embodiments in which the oxygen atom is located within the alkyl chain, for example -Ci -3 alkylOCi -3 alkyl, such as -CH2CH2OCH 3 or -CH2OCH 3 . Thus in one embodiment the alkoxy is linked through carbon to the remainder of the molecule. In one embodiment the alkoxy is linked through oxygen to the remainder of the molecule, for example -C 0 alkylOCi -6 alkyl. In one embodiment the disclosure relates to straight chain alkoxy.
  • Heteroalkyl as employed herein is intended to refer to a branched or straight chain alkyl wherein one or more, such as 1 , 2 or 3 carbons are replaced by a heteroatom, selected from N, O or S(0) q , wherein q represents 0, 1 or 2.
  • the heteroatom may replace a primary, secondary or tertiary carbon, that is, for example, SH, OH or NH 2 for CH 3 , or NH or O or S0 2 for -CH 2 - or N for a -CH- or a branched carbon group, as technically appropriate.
  • Haloalkyl refers to alkyl groups having 1 to 6 halogen atoms, for example 1 to 5 halogens, such as per haloalkyl, in particular perfluoroalkyl, more specifically
  • Ci -4 mono or C 2-8 di-acyl amino is intended to refer to -NHC(0)Ci -3 alkyl and to (-NC(0)Ci -3 alkyl) C(0)Ci -3 alkyl) respectively.
  • Ci -4 mono or C 2- 8 di-alkyl amino is intended to refer to -NHCi -4 alkyl and -N(Ci -4 alkyl) (Ci -4 alkyl) respectively.
  • Aryl as used herein refers to, for example C 6- i 4 mono or polycyclic groups having from 1 to 3 rings wherein at least one ring is aromatic including phenyl, naphthyl, anthracenyl, 1 ,2,3,4- tetrahydronaphthyl and the like, such as phenyl and naphthyl.
  • Heteroaryl is a 6 to 10 membered aromatic monocylic ring or bicyclic ring system wherein at least one ring is an aromatic nucleus comprising one or more, for example 1 , 2, 3 or 4 heteroatoms independently selected from O, N and S.
  • heteroaryls include: pyrrole, oxazole, thiazole, isothiazole, imidazole, pyrazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine, benzothiophene, benzofuran, or 1 , 2, 3 and 1 , 2, 4 triazole.
  • Heterocyclyl as employed herein refers to a 5 to 6 membered saturated or partially unsaturated non-aromatic ring comprising one or more, for example 1 , 2, 3 or 4 heteroatoms independently selected from O, N and S optionally one or two carbons in the ring may bear an oxo substituent.
  • the definition of C 5 - 6 heterocycle as employed herein refers to a is a 5 to 6 membered saturated or partially unsaturated non-aromatic carbocyclic ring comprising one or more, for example 1 , 2, 3 or 4 heteroatoms independently selected from O, N and S, wherein each heteroatom replaces a carbon atom and optionally one or two carbons may bear an oxo substitutent.
  • any valancies of a heteroatom not employed in forming or retaining the ring structure may be filled by hydrogen or a substituent, as appropriate.
  • subsituents on heterocycles may be on carbon or on a heteroatom, such as N as appropriate.
  • heterocycles and C 5- 6 heterocycles include pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, pyrazoline, imidazoline, pyrazolidine, imidazolidine, oxoimidazolidine, dioxolane, thiazolidine, isoxazolidine, pyran, dihydropyran, piperidine, piperazine, morpholine, dioxane, thiomorpholine and oxathiane.
  • Halogen includes fluoro, chloro, bromo or iodo, in particular fluoro, chloro or bromo, especially fluoro or chloro.
  • C 3 -8 cycloalkyl as employed herein is intended to refer to a saturated or partially unsaturated non-aromatic ring containing 3 to 8 carbon atoms.
  • C1-10 alkyl includes C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 or C 9 as well as Ci and C10
  • Co-8 alkyl includes Ci , C 2 , C 3 , C 4 , C 5 , C 6 , or C 7 as well as C 0 and C 8 .
  • a saturated or unsaturated, branched or unbranched CMO alkyl chain wherein at least one carbon (for example 1 , 2 or 3 carbons, suitably 1 or 2, in particular 1 ) is replaced by a heteroatom selected from O, N, S(0) p , wherein said chain is optionally, substituted by one or more groups independently selected from oxo, halogen, an aryl group, a heteroaryl group or a heterocyclyl group
  • the heteroatom may replace a primary, secondary or tertiary carbon, that is CH 3 , -CH 2 - or a -CH- or a branched carbon group, as technically appropriate.
  • R 1 is methyl, ethyl, propyl, / ' so-propyl, butyl or ie f-butyl, in particular ie f-butyl.
  • R 1 is -C(CH 3 )2CH 2 OH.
  • R 2 is methyl, ethyl, n-propyl, /so-propyl, n-butyl or ie f-butyl, in particular methyl.
  • R 2 is -CH 2 OH.
  • R 2 is in the 2, 3, or 4 position (i.e. ortho, meta or para position), in particular the para (4) position.
  • Ar is naphthyl
  • Ar is not substituted with optional substituents.
  • Ar is substituted with 1 or 2 groups.
  • Ar is phenyl optionally substituted by 1 or 2 substituents independently selected from Ci -3 alkyl or Ci -3 alkoxy, for example tolyl, xylyl, anisoyl, di-methoxybenzene or methoxy-methylbenzene.
  • the phenyl ring may, for example, be linked to the nitrogen of the urea through carbon 1 and and to the group L through carbon 4.
  • the optional one or two substituents selected from Ci -3 alkyl or Ci -3 alkoxy may be located in any of the unoccupied positions in the aromatic ring, for example in position 2 or in position 3 or in positions 2 and 3 or in positions 2 and 6 or in positions 3 and 5.
  • Embodiments encompassing other possible regioisomers also form an aspect of the present disclosure.
  • L is a straight chain linker, for example:
  • n 1 , 2, 3, 4, 5, 6, 7 or 8;
  • L is -OCH 2 -, -OCH 2 CH 2 -, -CH 2 0- or -CH 2 CH 2 0-.
  • L may represent -OCH 2 -.
  • L is a branched chain linker RO(CH 2 ) m wherein m is zero or an integer 1 , 2, 3, 4 or 5 and R a is a C 2-7 branched alkyl, with the proviso that the number of carbons in R a added to m is an integer from 2 to 7, especially where m is zero, such as -CH(CH 3 )0-, -C(CH 3 ) 2 0-, -CH 2 CH(CH 3 )0-, -CH(CH 3 )CH 2 0-, -C(CH 3 ) 2 CH 2 0- or -CH 2 C(CH 3 ) 2 0, in particular - CH(CH 3 )0-.
  • L is a branched chain linker (CH 2 ) n OR b wherein n is zero or an integer 1 , 2, 3, 4 or 5 and R b is a C 2-7 branched alkyl, with the proviso that the number of carbons in R b added to n is an integer from 2 to 7, for example n is zero, such as -OCH(CH 3 )-, -OC(CH 3 ) 2 -, -OCH 2 CH(CH 3 )-, -OCH(CH 3 )CH 2 -, -OC(CH 3 ) 2 CH 2 - or -OCH 2 C(CH 3 ) 2 and in particular -OCH(CH 3 )- or -OC(CH 3 ) 2 CH 2 -.
  • L is a branched chain linker ROR b wherein R a and R b are independently selected from a C2-7 branched alkylene with the proviso that the total number of carbons in R a and R b is an integer from 4 to 7.
  • L is a saturated unbranched Ci-C 8 alkylene chain or a saturated branched or unbranched C 2- 8 alkylene chain.
  • At least one carbon in L is replaced by -0-. In one embodiment L is -0-.
  • Alkylene as employed herein refers to branched or unbranched carbon radicals, such as methylene (-CH 2 -) or chains thereof. In the context of the present specification where alkyl is a linker then the latter is used interchangeably with the term alkylene.
  • the chain L includes 1 , 2 or 3 halogen atom substituents, independently selected from fluoro, chloro, and bromo, for example an alkylene carbon may incorporate one or two chlorine atoms or one or two fluorine atoms and a terminal carbon atom, for example of a branch of an alkylene chain, may be bonded to one, two or three fluorine atoms or one, two or three chlorine atoms to provide a radical such as a trifluoromethyl or a trichloromethyl group.
  • halogen atom substituents independently selected from fluoro, chloro, and bromo
  • an alkylene carbon may incorporate one or two chlorine atoms or one or two fluorine atoms and a terminal carbon atom, for example of a branch of an alkylene chain, may be bonded to one, two or three fluorine atoms or one, two or three chlorine atoms to provide a radical such as a trifluoromethyl or a trichloromethyl group.
  • the chain L does not include a halogen atom or atoms.
  • R 3 is H.
  • R 3 is methyl, ethyl, n-propyl or / ' so-propyl.
  • R 3 is cyclopropyl.
  • X is selected from, pyrrole, oxazole, thiazole, isothiazole, imidazole, pyrazole, isoxazole, oxadiazole, pyridazine, pyrimidine, pyrazine, or 1 ,2,3 and 1 ,2,4 triazole, such as pyrazole, isoxazole, oxadiazole, pyridine, pyridazine, pyrimidine, pyrazine, or 1 ,2,3 and 1 ,2,4 triazole, in particular, pyrimidine, imidazole or pyridine, and especially pyridine or pyrimidine, more specifically pyridine.
  • carbon atoms are replaced in the alkyl chain of Q by heteroatoms independently selected from O, N, S(0) p .
  • heteroatom(s) replacing carbon(s) in the alkyl chain fragment of Q are selected from N and O.
  • Q is a saturated or unsaturated, branched or unbranched Ci -8 alkyl chain or a C1-6 alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from -O, - N, S(0) p .
  • the alkyl chain may be a C 2-8 alkyl or a C 3 - 6 alkyl group, such as a C 4 alkyl or a C 5 alkyl group.
  • a nitrogen atom in the alkyl chain is directly bonded to the carbonyl of the fragment -NR 3 C(0) and additionally may, for example, be a terminal amino group.
  • Q represents Ci -6 alkylNH 2 or NH 2 .
  • Q represents -NHCi -6 alkyl such as -NHCH 3 or -NHCH 2 CH 3 or -NHCH(CH 3 ) 2 .
  • the fragment Q is a saturated or unsaturated, branched or unbranched CMO alkyl chain wherein at least one carbon (for example 1 , 2, 3 or 4 carbons, in particular 1 or 2 carbons) is replaced by a heteroatom selected from O, N, S(0) p , for example in such a manner as to provide a stable /V-acyl group, NR 3 C(0)Q, wherein said chain is optionally substituted by one or more groups selected from oxo, halogen, an aryl group, a heteroaryl group, a heterocyclyl group, or or C 3-8 cycloalkyl each aryl, heteroaryl or heterocyclyl or C 3-8 cycloalkyl group bearing 0 to 3 substituents independently selected from a relevant substituent listed above for compounds of formula (I).
  • the fragment Q is a saturated or unsaturated, branched or unbranched CMO alkyl chain wherein at least one carbon (for example 1 , 2, 3 or 4 carbons, in particular 1 or 2 carbons) is replaced by a heteroatom selected from O, N, S(0) p , for example in such a manner as to provide a stable /V-acyl group, NR 3 C(0)Q, wherein said chain is optionally substituted by one or more groups selected from oxo, halogen, an aryl group, a heteroaryl group or a heterocyclyl group, each aryl, heteroaryl or heterocyclyl group bearing 0 to 3 substituents independently selected from a relevant substituent listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono or C 2-8 di-alkyl amino and Ci -4 mono or C 2-8 di-acyl amino.
  • halogen Ci -6 al
  • the latter chain is optionally substituted by one or more groups selected from oxo, halogen, an aryl group, a heteroaryl group or a heterocyclyl group, each aryl, heteroaryl or heterocyclyl group bearing 0 to 3 substituents selected from halogen, Ci -6 alkyl, C-i-6 alkoxy, Ci -6 haloalkyl, amino, and Ci -4 mono or C 2-8 di-alkyl amino.
  • Q is Ci -4 alkyl-V-R 4 , such as Ci -3 alkyl-V-R 4 wherein:
  • V is a heteroatom selected from NR V , O or S(0) p ;
  • R v represents H or Ci -3 alkyl
  • R 4 is H or -Ci -3 alkyl, and p is as defined above,
  • the total alkyl chain length is not more than 10 carbon atoms, including replacement heteroatoms and that the resulting radical Q is a stable group, for example -CH 2 SCH 3, -CH 2 S0 2 CH 3 , -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 -C(CH 3 ) 2 NHCH 3 , -CH(CH 3 )N(CH 3 ) 2 , -(CH 2 ) 3 CHNHCH 3, -(CH 2 ) 3 N(CH 3 ) 2 , -CH 2 OH, -CH 2 OCH 3 , -CH(CH 3 )OCH 3 , or -(CH 2 ) 2 OCH 3 .
  • Q is Ci -3 alkyl-V-(Ci -3 alkyl-Z-R 5 ) k such as Ci -3 alkyl-V-(C 2- 3 alkyl-Z-R 5 ) k wherein:
  • V is a heteroatom selected from N, NH, O or S(0) p , such as N or NH
  • Z is independently selected from NH, O or S(0) p ;
  • R 5 is H or -Ci -3 alkyl
  • k is an integer 1 or 2 (such as 1 );
  • Q is Ci. 3 alkyl-V-Ci -3 alkyl-OCH 3 for example Ci -3 alkyl-V-C 2 - 3 alkyl-OCH 3 such as Ci -3 alkyl-V-(CH 2 ) 2 0CH 3 , in particular -CH 2 0(CH 2 ) 2 OCH 3 and CH 2 S(CH 2 ) 2 OCH 3 , or -CH 2 NH(CH 2 ) 2 OCH 3 , d -3 alkyl-V-(Ci.
  • alkyl-OCH 3 ) k wherein k represents 2, for example Ci -3 alkyl-V-(C 2-3 alkyl-OCH 3 ) k such as- CH 2 N[(CH 2 ) 2 OCH 3 ] 2 .
  • Q is Ci -3 alkyl-V-Ci -2 alkyl-Z-Ci -2 alkyl-Y-R 6 , or Ci -3 alkyl-V-C 2-3 alkyl-Z-C 2-3 alkyl-Y-R 6 , wherein V, Z and Y are independently a heteroatom selected from NH, O or S(0) p , R 6 is H or methyl, and
  • Q is -CH 2 V(CH 2 ) 2 0(CH 2 ) 2 OCH 3 , such as -CH 2 0(CH 2 ) 2 0(CH 2 ) 2 OCH 3 , or alternatively -CH 2 NH(CH 2 ) 2 0(CH 2 ) 2 OCH 3, or-CH 2 S(CH 2 ) 2 0(CH 2 ) 2 OCH 3 .
  • Q represents -NR 7 R 8 and -NR 3 C(0)Q forms a urea, where R 7 and R 8 independently represent hydrogen or a Ci -9 saturated or unsaturated, branched or unbranched alkyl chain, wherein one or more carbons, such as 1 , 2 or 3 are optionally replaced by a heteroatom selected from O, N or S(0) p .
  • Said chain is optionally substituted by one or more groups independently selected from oxo, halogen, an aryl group, a heteroaryl group, a heterocyclyl or C 3-8 cycloalkyl group, each aryl, heteroaryl or heterocyclyl group bearing 0 to 3 substituents independently selected from the relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono or C 2- 8 di-alkyl amino and Ci -4 mono or C 2-8 di-acyl amino with the proviso that the total alkyl chain length is not more than 10 carbon atoms, including replacement heteroatoms and that the resulting radical Q is a stable group.
  • groups independently selected from oxo, halogen, an aryl group, a heteroaryl group, a heterocyclyl or C 3-8 cycloalkyl group, each aryl, heteroaryl or heterocycly
  • Q represents -NR 7 R 8 and -NR 3 C(0)Q forms a urea, where R 7 and R 8 independently represent hydrogen or a Ci -9 saturated or unsaturated, branched or unbranched alkyl chain, wherein one or more carbons, such as 1 , 2 or 3 are optionally replaced by a heteroatom selected from O, N or S(0) p .
  • Said chain is optionally substituted by one or more groups independently selected from oxo, halogen, an aryl group, a heteroaryl group or a heterocyclyl group, each aryl, heteroaryl or heterocyclyl group bearing 0 to 3 substituents independently selected from the relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono or C 2-8 di-alkyl amino and Ci -4 mono or C 2-8 di-acyl amino with the proviso that the total alkyl chain length is not more than 10 carbon atoms, including replacement heteroatoms and that the resulting radical Q is a stable group.
  • groups independently selected from oxo, halogen, an aryl group, a heteroaryl group or a heterocyclyl group, each aryl, heteroaryl or heterocyclyl group bearing 0 to 3 substituents independently selected from the relevant substituents listed above
  • R 7 represents hydrogen
  • ureas include those in which R 7 and R 8 are both hydrogen and Q is -NH 2 , or where Q is -IMHCH 3 or -N(CH 3 ) 2 to provide, for example, a fragment -NR 3 C(0)NH 2 or -NR 3 C(0)NHCH 3 or -NR 3 C(0)N(CH 3 ) 2 .
  • ureas containing a heteroatom in the alkyl chain include those in which Q is - NH(CH 2 ) 2 OCH 3 or -N[(CH 2 ) 2 OCH 3 )] 2 .
  • Q represents -NHC 2-6 alkylOCi -3 alkyl, such as-NHCH 2 CH 2 OCH 3 .
  • ureas containing an oxo substitutent include those in which Q is -NHCH 2 C(0)NH-C 2-3 alkyl-X 1 -Ci -3 alkyl, wherein X 1 is a heteroatom selected from N, O or S(0) p and p is defined as above. Examples of the latter include those wherein Q is -NHCH 2 C(0)NHCH 2 CH 2 OCH 3 . Thus in one embodiment Q represents -NHCi -4 alkylC(0)NHC 2 alkylOCH 3 such as-NHCH 2 C(0)NHCH 2 CH 2 OCH 3 .
  • Q represents -NHCi -4 alkylC(0)R Q wherein R Q is selected from OH or - NR'R" where R' is hydrogen or Ci -3 alkyl and R" is hydrogen or Ci -3 alkyl, for example -NHCH 2 C(0)OH, -NHCH 2 C(0)NH 2 or -NHCH 2 C(0)NHCH 3 such as -NHCH 2 C(0)OH or -NHCH 2 C(0)NHCH 3 .
  • the radical Q represents -NHCi -4 alkylC(0)OCi -3 alkyl, such as -NHCH 2 C(0)OCH 2 CH 3 .
  • Q represents -N-R 9 Ci -3 alkyl-V-(Ci -3 alkyl-Z-R 10 ) k for example -N-R 9 C 2-3 alkyl-V-(C 2-3 alkyl-Z-R 10 ) k wherein:
  • V represents N, NH, O, S(0) p ;
  • Z represents NH, O, S(0) p ;
  • k is an integer 1 or 2;
  • p is an integer 0, 1 or 2
  • R 9 represents H or Ci -3 alkyl-V-(Ci -3 alkyl-Z-R 10 ) k such as C 2-3 alkyl-V-(C 2-3 alkyl-Z-R 10 ) k ;
  • R 10 is H or Ci -3 alkyl such as Ci -3 alkyl
  • the total alkyl chain length is not more than 10 carbon atoms, including replacement heteroatoms and that the resulting radical Q is a stable group.
  • Q is a saturated or unsaturated, branched or unbranched CMO alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N, and S(0) p , wherein said chain is substituted by an aryl group bearing 0 to 3 substituents, for example 1 , 2 or 3, such as 1 or 2 substituents independently selected from the relevant substituents listed above for compounds of formula (I), for example from halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino and Ci -4 mono or C 2-8 di-alkyl amino and Ci -4 mono or C 2-8 di-acyl amino, such as a saturated or unsaturated, branched or unbranched CMO alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N, and S(0) p , wherein said chain is substituted by an aryl group bearing 0 to 3 substituents, for example 1 , 2 or 3, such as 1 or 2
  • the said aryl group is phenyl, for example substituted phenyl or unsubstituted phenyl.
  • Q represents -NHC 0- 6 alkylphenyl, such as -NHphenyl or NHbenzyl.
  • -NR 3 C(0)CH 2 NHCH 2 C 6 H 4 such as -NHC(0)CH 2 NHCH 2 C 6 H 4 (OCH 3 ), for example where the methoxy substituent is in the ortho, meta or para position, such as the para position.
  • Q is a saturated or unsaturated, branched or unbranched CMO alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N, and S(0) p , wherein said chain is substituted by a heteroaryl group bearing 0 to 3 substituents (for example 1 , 2 or 3, such as 1 or 2 substituents) independently selected from the relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 alkyl amino, Ci -4 mono or C 2-8 di-alkyl amino and Ci -4 mono or C 2-8 di-acyl amino, such as a saturated or unsaturated, branched or unbranched CMO alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N, and S(0) p , wherein said chain is substituted by a heteroaryl group bearing 0 to 3 substituents for example 1 , 2 or 3, such as 1 or 2 substituents
  • the said heteroaryl group is selected from, thiophene, oxazole, thiazole, isothiazole, imidazole, pyrazole, isoxazole, isothiazole, oxadiazole, 1 ,2,3 or 1 ,2,4 triazole, pyridine, pyridazine, pyrimidine, pyrazine and, in particular pyridine and pyrimidine, especially pyridine.
  • Q represents -NHCi -6 alkylheteroaryl, for example -NH(CH 2 ) 3 imidazolyl or -NHCH 2 isoxazole wherein the isoxazole is optionally substituted such as -NHCH 2 isoxazole(CH 3 ) .
  • Q represents -NHCi -4 alkylC(0)NHCi -3 alkylheteroaryl, for example a nitrogen containing heteroaryl group or a nitrogen and oxygen containing heteroaryl, more specifically -NHCH 2 C(0)NHCH 2 CH 2 pyridinyl, in particular where pyridinyl is linked through carbon, for example pyridin-4-yl or -NHCH 2 C(0)NHCH 2 CH 2 CH 2 imidazolyl, in particular where imidazolyl is linked through nitrogen.
  • Q is a saturated or unsaturated, branched or unbranched CMO alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N and S(0) p wherein said chain is substituted by a heterocyclyl group bearing 0 to 3 substituents (for example 1 , 2 or 3, such as 1 or 2 substituents) independently selected from the relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl amino, Ci -4 mono or C 2- 8 di-alkyl amino and Ci -4 mono or C 2- 8 di-acyl amino, such as a saturated or unsaturated, branched or unbranched CMO alkyl chain, wherein at least one carbon is replaced by a heteroatom selected from O, N and S(0) p wherein said chain is substituted by a heterocyclyl group bearing 0 to 3 substituents, for example 1 , 2 or 3, such as 1 or 2 substituents
  • said heterocyclyl is selected, from a 5 or 6 membered saturated or partially unsaturated ring system comprising one or more (for example 1 , 2 or 3 in particular 1 or 2) heteroatoms independently selected from O, N and S, for example pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, morpholine, 1 ,4-dioxane, pyrrolidine and oxoimidazolidine such as pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, morpholine, and 1 ,4-dioxane, in particular piperidine, piperazine, and morpholine.
  • pyrrolidine tetrahydrofuran, tetrahydrothiophene
  • piperidine piperazine, morpholine
  • 1 ,4-dioxane in particular piperidine, piperazine, and
  • a heterocyclic group may be linked to the alkyl chain of Q or to the carbonyl of -NR 3 C(0)- through carbon or nitrogen, in particular a nitrogen atom.
  • Q is -C 0-3 alkylheterocycle (for example-C 0 -ialkylheterocycle) said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, in particular 1 or 2, heteroatoms) selected from O, N and S, and is optionally substituted by one or two or three groups independently selected from the relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2- 8 di-alkyl amino and Ci -4 mono or C 2- 8 di-acyl amino.
  • heteroatom for example 1 , 2 or 3, in particular 1 or 2, heteroatoms
  • Q is -C 0 alkylheterocycle, for example a tetrahydropyranyl or a pyrrolidinyl or a morpholinyl or a piperazinyl or an oxoimidazolinyl group, such as 2-oxoimidazolidinyl group.
  • the heterocycle is linked through carbon, and is, for example, a C-linked tetrahydropyran or a C-linked piperidine or a C-linked morpholine or a C-linked piperazine.
  • the heterocyclic group containing one or more N atoms is linked through N.
  • This embodiment provides for ureas in which one of the urea nitrogens is embedded within a heterocyclic ring. Examples of this embodiment include, but are not limited to, an /V-linked morpholine or an /V-linked piperidine or an /V-linked piperazine, said /V-linked piperizinyl group optionally bearing an additional C- or N- substituent (such as an N- methyl group or /V-CH 2 CH 2 OCH 3 group .
  • Q is a heterocyclyl linked through nitrogen such as piperidinyl, in particular 4-hydroxypiperidinyl or piperazinyl, such as 4-methyl pierazinyl.
  • Q represents a heterocyclyl group, for example a nitrogen containing heterocyclyl group, in particular linked through N, such as morpholinyl or piperazinyl optionally substituted by methyl, especially 4-methyl, or piperidinyl.
  • Q is a -C-ialkylheterocycle, for example tetrahydropyranylmethyl or a C- or /V-linked piperazinylmethyl optionally bearing a substituent (for example a Ci -6 alkyl substitutent such as methyl or a Ci -6 alkoxy substituent such as -CH2CH2OCH 3 ).
  • a substituent for example a Ci -6 alkyl substitutent such as methyl or a Ci -6 alkoxy substituent such as -CH2CH2OCH 3
  • Additional examples include a C- or /V-linked pyrrolidinylmethyl, or a C- or N- linked oxoimidazolinylmethyl (such as 2-oxoimidazolidinylmethyl, said heterocycle optionally bearing a substitutent (such as /V-methyl
  • Q represents -NHheterocyclyl (wherein the heterocyclyl bears 0 to 3 substituents selected from the relevant list of substituents listed above for compounds of formula (I), for example halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono or C 2- 8 di-alkyl amino, -S(0) q Ci -6 alkyl, Ci -4 mono or C 2-8 di-acyl amino, C 0- 6 alkylC(0)Ci -6 alkyl or C 0- 6 alkylC(0)Ci -6 heteroalkyl), such as where the ring is linked through carbon, for example 2-piperidinyl or 3-piperidinyl or 4-piperidinyl, in particular 1 -acetylpiperidin-4-yl, 1 - methylpiperidin-4-yl, 1 -(methylsulfonyl)piperidin-4-yl or 1 -(2-(2-methoxy
  • Q represents -NHCi -6 alkylheterocyclyl for example a nitrogen containing heterocyclyl group, in particular one linked through nitrogen, such as -NHCH 2 CH 2 morpholine, -NH(CH 2 ) 3 morpholine or -NH(CH 2 ) 4 morpholine.
  • Q represents -NHCi -6 alkylC(0)heterocyclyl (wherein the heterocyclyl bears 0 to 3 substituents selected from the relevant list of substituents listed above for compounds of formula (I), for example halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono or C 2-8 di-alkyl amino, Ci -4 mono or C 2-8 di-acyl amino, C 0- 6 alkylC(0)Ci -6 alkyl or Co-6 alkylC(0)Ci- 6 heteroalkyl) for example a nitrogen containing heterocyclyl group, in particular one linked through nitrogen, such as -NHCH 2 C(0)-1 -pyrrolindinyl,-NHCH 2 C(0)-1 - piperidinyl, -NHCH 2 C(0)-4-morpholinyl or alternatively
  • -NHCH 2 C(0)piperazinyl such as -NHCH 2 C(0)-4-methyl-1 -piperazinyl.
  • Q represents -NHCi -4 alkylC(0)NHCi -3 alkylheterocyclyl for example a nitrogen containing heterocyclyl group or a nitrogen and/or oxygen containing heterocyclyl, such as -NHCH 2 C(0)NHCH 2 CH 2 morpholinyl, in particular where morpholinyl is linked through nitrogen.
  • Q represents -N(Ci -3 alkyl)Ci -6 alkylheterocyclyl, for example a nitrogen containing heterocyclyl group, in particular linked through nitrogen, such as -N(CH 3 )CH 2 CH 2 morpholine, -N(CH 3 )(CH 2 ) 3 morpholine or -N(CH 3 )(CH 2 ) 4 morpholine.
  • Q is -Ci -3 alkyl-G-Ci -3 alkylheterocycle wherein G is a heteroatom selected from NH, O or S(0) p said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, in particular 1 or 2, heteroatoms) selected from O, N, and S, and is optionally substituted by one or two or three groups independently selected from relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2-8 di-alkyl amino and Ci -4 mono or C 2-8 di-acyl amino such as one or two or three groups halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2 -8 di-alkyl amino.
  • G is a heteroatom selected from NH, O or S(0) p said heterocyclyl group comprising
  • Q is -CH 2 G(CH 2 )2heterocycle for example -CH 2 G(CH 2 )2tetrahydropyranyl; or -CH 2 G(CH 2 ) 2 morpholinyl in which the heterocyclyl is linked through nitrogen or carbon; or CH 2 G(CH 2 ) 2 piperazinyl in which the heterocyclyl is linked through nitrogen or carbon and optionally bearing a further C- or N- substituent (for example a C1-6 alkyl substitutent such as methyl or a Ci -6 alkoxy substituent such as -CH 2 CH 2 OCH 3 ); or - CH 2 G(CH 2 ) 2 pyrrolidinyl, in which the heterocyclyl is linked through nitogen or carbon, for example linked through nitrogen; or -CH 2 G(CH 2 ) 2 oxoimidazolinyl (such as 2-oxoimidazolidinyl) for example linked through N and optionally bearing an additional C- or N- substituten
  • G is O. In one embodiment G is NH. In one embodiment Q is a saturated or unsaturated CMO alkyl chain wherein at least one carbon (for example 1 , 2 or 3 carbons) is replaced by a heteroatom selected from O, N, S(0) p wherein said chain is substituted by a C 3 - 8 carbocyclyl group and said alkyl chain is optionally substituted by one or more (for example 1 or 2) groups selected from oxo and halogen.
  • CMO alkyl chain wherein at least one carbon (for example 1 , 2 or 3 carbons) is replaced by a heteroatom selected from O, N, S(0) p wherein said chain is substituted by a C 3 - 8 carbocyclyl group and said alkyl chain is optionally substituted by one or more (for example 1 or 2) groups selected from oxo and halogen.
  • said C 3- 8 carbocyclyl group bears one or more groups (for example 1 , 2 or 3 groups) independently selected from halogen, hydroxyl, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono or C 2-8 di-alkyl amino, Ci -4 mono or C 2-8 di-acyl amino, S(0) q Ci -6 alkyl, C 0- 6 alkylC(0)Ci -6 alkyl or C 0-6 alkylC(0)d -6 heteroalkyl.
  • groups for example 1 , 2 or 3 groups
  • Q represents -NHC 3-6 cycloalkyl, such as -NHcyclopropyl, -NHcyclopentyl or -NHcyclohexyl.
  • the aryl, heteroaryl or heterocyclyl group bears at least one -S(0) q Ci-6 alkyl substitutent and optionally bears one or two further relevant substituents independently selected from the list of substituents defined above for compounds of formula (I).
  • the C 5 - 6 heterocycle bears at least one -S(0) q Ci -6 alkyl substitutent and optionally bears one or two further substituents independently selected from the relevant list of substituents defined above for compounds of formula (I).
  • the aryl, heteroaryl or heterocyclyl group bears at least one hydroxyl substituent and optionally bears one or two further substituents independently selected from the relevant list of substituents defined above for compounds of formula (I).
  • the C 5 - 6 heterocycle bears at least one hydroxyl substituent and optionally bears one or two further substituents independently selected from the relevant list of substituents defined above for compounds of formula (I).
  • aryl, heteroaryl or heterocyclyl group bears at least one Ci -4 mono and/or C 2- 8 di-acyl amino substituent and optionally bears one or two further substituents independently selected from the relevant list defined above for compounds of formula (I).
  • the C 5 - 6 heterocycle bears at least one Ci -4 mono and/or C 2- 8 di-acyl amino substituent and optionally bears one or two further substituents independently selected from the relevant list defined above for compounds of formula (I).
  • aryl, heteroaryl or heterocyclyl group bears at least one C 0- 6 alkylC(0)Ci- 6 heteroalkyl substituent and optionally bears one or two further substituents independently selected from the relevant list defined above for compounds of formula (I).
  • the C 5-6 heterocycle bears at least one C 0- 6 alkylC(0)Ci -6 heteroalkyl substituent and optionally bears one or two further substituents independently selected from the relevant list defined above for compounds of formula (I).
  • aryl, heteroaryl or heterocyclyl group bears at least one C 0- 6 alkylC(0)Ci- 6 alkyl substituent and optionally bears one or two further substituents independently selected from the relevant list defined above for compounds of formula (I).
  • the C 5-6 heterocycle bears at least one C 0- 6 alkylC(0)Ci -6 alkyl substituent and optionally bears one or two further substituents independently selected from the relevant substituents defined above for compounds of formula (I).
  • Q represents tetrahydrofuranyl, morpholinyl, piperidinyl such as piperidinyl bearing one hyroxyl substituent, piperazinyl such as piperazinyl bearing one methyl substituent or pyrrolidinyl such a pyrrolidinyl bearing one di-methyl amino substituent.
  • the ring may be linked through the heteroatom, such as nitrogen. Alternatively, the ring may be linked through carbon.
  • the substituent may, for example be para relative to the atom through which the ring is linked to the remainder of the molecule.
  • the alkyl chain fragment of Q does not bear any optional substituents.
  • the alkyl chain is saturated.
  • the alkyl chain is unbranched.
  • the alkyl chain fragment of Q bears 1 , 2, or 3, for example 1 or 2, in particular 1 optional substituent.
  • the heteroatom may replace a primary, secondary or tertiary carbon, that is a CH 3 , -CH 2 - or a -CH-, group, as technically appropriate.
  • p is 0 or 2.
  • p is 1.
  • compounds of the disclosure include those in which the fragment -NR 3 C(0)Q in formula (I) is represented by:
  • -NR 3 C(0)CH 2 OCi -6 alkyl in particular -NR 3 C(0)CH 2 OCH 3 , especially -NHC(0)CH 2 OCH 3 ;
  • -NR 3 C(0)(CH 2 ) 2 OCi -6 alkyl such as -NR 3 C(0)(CH 2 ) 2 OCH 3 , in particular-NHC(0)(CH 2 ) 2 OCH 3 ; -NR 3 C(0)(CH 2 ) 3 NHCi -3 alkyl, and in particular -NHC(0)(CH 2 ) 3 NHCH 3 ;
  • -NR 3 C(0)NHCi-9 alkyl such as NR 3 C(0)NHCi -7 alkyl, and in particular -NHC(0)NHCH 3
  • compounds of the disclosure include compounds of formula (I) in which the fragment -NR 3 C(O)C 0-8 alkylheterocyclyl is represented by:
  • -NHC(0)-(morpholinyl) such as -NHC(0)-(4-morpholinyl) or -NHC(0)-(3-morpholinyl);
  • -NHC(0)-(oxoimidazolidinyl) such as -NHC(0)-(2-oxoimidazolidinyl), in particular -NHC(0)-(2- oxoimidazolidin-1 -yl);
  • These fragments may optionally terminate in an aryl group, a heteroaryl group a heterocyclyl group or C 3 -8 cycloalkyl group, such as an aryl group, a heteroaryl group a heterocyclyl group as defined for fragment Q above.
  • the disclosure relates to compounds of formula (IA):
  • R 1 , R 2 , Ar, L, R 3 and Q are as defined above.
  • the substituent -NR 3 C(0)Q is in the 2 or 3 position.
  • the disclosure relates to compounds of formula (IB): wherein R 1 , R 2 , Ar, L, R 3 and Q are as defined above.
  • R 1 , R 2 , Ar, L and R 3 are as defined above and p is 0, 1 or 2, in particular 0 or 2, and x is an integer from 1 to 6 (including 2, 3, 4 and 5) and y is zero or an integer from 1 to 5 (including 2, 3 and 4) with the proviso that the sum of x and y is an integer from 1 to 8 such as 1 to 6, for example x is 1 and y is 1.
  • R 1 , R 2 , Ar, L and R 3 are as defined above
  • x is an integer from 1 to 6 (including 2, 3, 4 and 5) and y is zero or an integer from 1 to 5 (including 2, 3 and 4), with the proviso that the sum of xand y is an integer from 1 to 6, for example x is 1 and y is 0.
  • the fragment represented by -NR 3 C(0)(CH 2 ) x O(CH 2 ) y CH 3 is: -NR 3 C(0)CH 2 OCH 3 , especially -NHC(0)CH 2 OCH 3 .
  • the disclosure relates to compounds of formula (IE): wherein R 1 , R 2 , Ar, L, R 3 , R 7 and R 8 are as defined above. In one embodiment the disclosure relates to compounds of formula (IF):
  • R 1 is Ci -6 alkyl optionally substituted by a hydroxyl group
  • R 2 is H or C 1 -6 alkyl optionally substituted by a hydroxyl group
  • R 3 is H, Ci-6 alkyl or C 0-3 alkylC 3 - 6 cycloalkyl
  • Ar is a naphthyl or a phenyl ring either of which may be optionally substituted by one or more groups independently selected from Ci -6 alkyl, Ci -6 alkoxy, amino, Ci -4 mono or C 2- 8 di-alkyl amino;
  • X is 5 or 6 membered heteroaryl group containing at least one nitrogen atom
  • Q is selected from:
  • a Co-8 alkylC 5- 6 heterocycle or said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, suitably 1 or 2, in particular 1 heteroatom) selected from O, N, and S, and is optionally substituted by one, two or three groups independently selected from halogen, hydroxyl, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2- 8 di-alkyl amino, Ci -4 mono or C 2- 8 di-acyl amino, S(0) q Ci -6 alkyl, C 0-6 alkylC(0)d -6 alkyl or C 0-6 alkylC(0)Ci -6 heteroalkyl; and
  • p 0, 1 or 2;
  • R 1 , R 2 , Ar, R 3 and Q are as defined above.
  • R 1 , R 2 , Ar, R 3 and Q are as defined above.
  • the disclosure relates to compounds of formula (IK): wherein R 1 , R 2 , Ar and R 3 are as defined above and
  • Z represents a saturated or unsaturated, branched or unbranched Ci -9 alkyl chain, wherein at least one carbon (for example 1 , 2 or 3 carbons, suitably 1 or 2, in particular 1 ) is replaced by a heteroatom selected from O, N, S(0) p , or
  • a Co-7 alkylC 5- 6 heterocycle said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, suitably 1 or 2, in particular 1 heteroatom) selected from O, N and S, and is optionally substituted by one or two or three groups independently selected from the relevant substituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2-8 di-alkyl amino.
  • heteroatom for example 1 , 2 or 3, suitably 1 or 2, in particular 1 heteroatom
  • Z is -OCH 3 or -OCH2CH 2 OCH 3 .
  • Z is -S0 2 CH 3 .
  • Z is -NR A R B wherein R A and R B are independently selected from hydrogen, Ci -6 alkyl, and C 3 - 6 alkoxy such that for example Z represents -NH 2 , -IMHCH3, -N(CH 3 ) 2 or -NHCH 2 CH 2 OCH 3 .
  • Z is -S(0) q CH 3 wherein n is 0, 1 or 2, such as 0 or 2.
  • Z represents a -C 5 - 6 heterocycle said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, suitably 1 or 2, in particular 1 heteroatom) selected from O, N and S, and is optionally substituted by one, two or three groups independently selected from the relevant substituents listed above for compounds of formula (I) for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2-8 di-alkyl amino, for example:
  • piperazinyl (in particular linked through nitrogen) optionally substituted on the second nitrogen by -CH 3 or -CH 2 CH 2 OCH 3 .
  • the disclosure relates to compounds of formula (IL): wherein R 1 , R 2 , Ar and R 3 are as defined above and
  • R 7 and R 8 independently represent hydrogen, Ci -6 alkyl, or
  • R 7 and R 8 together with the nitrogen to which they are attached represent a 5 or 6 membered heterocycle optionally comprising a further heteroatom selected from O, N and S, wherein said heterocycle is optionally substituted by one or two or three groups independently selected from the relevant sustituents listed above for compounds of formula (I), for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2-8 di-alkyl amino.
  • the group -NR 7 R 8 represents -NH 2 , -NHCH 3 or NHCH 2 CH 3 .
  • R 1 , R 2 , Ar and R 3 are as defined above and
  • Het represents a C 5 - 6 heterocycle said heterocyclyl group comprising at least one heteroatom (for example 1 , 2 or 3, suitably 1 or 2, in particular 1 heteroatom) selected from O, N and S, and is optionally substituted by one or two or three groups independently selected from the relevant substituents listed above for compounds of formula (I) for example halogen, Ci -6 alkyl, Ci -6 alkoxy, Ci -6 haloalkyl, amino, Ci -4 mono and C 2- 8 di-alkyl amino.
  • Het is morpholinyl or tetrahydropyranyl.
  • the compound is: /V-(4-((4-(3-(3-ie/f-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 -yloxy)methyl)pyridin-2- yl)-2-methoxyacetamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.
  • the compound is:
  • salts of compound (I) include all pharmaceutically acceptable salts, such as, without limitation, acid addition salts of mineral acids such as HCI and HBr salts and addition salts of organic acids such as a methansulfonic acid salt.
  • solvates of compounds of formula (I) include hydrates.
  • the compounds of the disclosure include those where the atom specified is a naturally occurring or non-naturally occurring isotope.
  • the isotope is a stable isotope.
  • the compounds of the disclosure include, for example deuterium containing compounds and the like.
  • the compounds described herein may include one or more chiral centres, and the disclosure extends to include racemates, both enantiomers (for example each substantially free of the other enantiomer) and all stereoisomers resulting therefrom.
  • one enantiomeric form is present in a substantially purified form that is substantially free of the corresponding entaniomeric form.
  • LG-i is a leaving group for example halogen, such as chloro.
  • the reaction is suitably carried out in the presence of a base (e.g. DIPEA).
  • a base e.g. DIPEA
  • the reaction is suitably carried out in an aprotic solvent or solvent mixture, e.g. DCM and DMF.
  • LG 2 and LG 3 each independently represent leaving groups (e.g. LG 2 and LG 3 both represent imidazolyl followed by reaction with a compound of formula (V):
  • the reaction is suitably carried out in an aprotic solvent (e.g. dichloromethane), using appropriate protecting groups for chemically sensitive groups and a base, for example DIPEA.
  • aprotic solvent e.g. dichloromethane
  • protecting groups for chemically sensitive groups and a base for example DIPEA.
  • the reaction may be performed in the presence of a sterically hindered base such as DIPEA, in a suitable inert solvent such as dichloromethane.
  • a sterically hindered base such as DIPEA
  • a suitable inert solvent such as dichloromethane.
  • DIPEA inert solvent
  • a suitable inert solvent such as dichloromethane
  • Compounds of formula (I) wherein R 2 is a hydroxyalkyl may be prepared by reacting a (hydrazinylphenyl)alkanoic acid with an alkanoyl acetonitrile such as R 1 C(0)CH 2 CN, for example.
  • the coupling may be effected in presence of an alcohol solvent such as ethanol and a mineral acid, such as HCI followed by treatment with a lithium hydroxide in a solvent such as THF.
  • the substituent R 2 comprising a hydroxyalkyl may be revealed by a reduction employing borane in a suitable solvent, for example THF to afford a compound of formula (IV) where R 2 is hydroxylated alkyl.
  • the hydroxyl may then be protected, for example as a silyl ether and and (IV) carried through one of the routes described elsewhere in this section to generate a compound of formula (I) in which R 2 is a protected hydroxyalkyl group.
  • the hydroxyl can be revealed by cleavage of the sillyl group, for example with tetrabutylammonium fluoride.
  • a compound of formula (IVa) can be prepared by reacting a compound of formula (IV) with phosgene or a phosgene equivalent such as diphosgene or triphosgene in the presence of a base such DIPEA. It will be understood by persons skilled in the art that the compound of formula (IVa) is generally a reactive intermediate, and may be isolated and used directly in subsequent transformations or may be a transient intermediate, that is generated in situ and used without isolation.
  • the reaction may be performed in the presence of a sterically hindered base such as DIPEA, in a suitable inert solvent such as dichloromethane.
  • a sterically hindered base such as DIPEA
  • a suitable inert solvent such as dichloromethane.
  • a compound of (IVb) can be prepared by reacting a compound of formula (IV) with a compound of formula (VI) in the presence of a base such as DIPEA. It will be understood by persons skilled in the art that the compound of formula (IVb) may be an intermediate, including a transient intermediate, that is not isolated.
  • a compound of formula (V) may be prepared by reduction of a compound of formula (VII):
  • Ar, L, X and R 3 are as defined above for compounds of formula (I), for example by hydrogenation in the presence of a catalyst such as platinum supported on carbon.
  • the reaction is suitably carried out in polar protic solvent or mixture of solvents (e.g. methanol and acetic acid).
  • polar protic solvent or mixture of solvents e.g. methanol and acetic acid.
  • a compound of formula (V) where L is O may be prepared by deprotecting a compound of formula (Vila):
  • P 1 , P 2 and P 3 are protecting groups and R 3 is a protecting group, for example acetyl such as -C(0)CH 2 OCH 3 or R 3 as defined above for compounds of formula (I).
  • a compound of formula (VII) wherein L represents -(CH 2 )nO(CH2) m or (CH 2 ) n OR b , as defined above, wherein n is zero and the linker L contains at least one -CH 2 - may be prepared by reaction of a compound of formula (Villa) or (Vlllb):
  • R 3 is a protecting group or R 3 as defined above for compounds of formula (I) with a compound of formula (IX) or (X):
  • the reaction may be performed under Mitsunobu conditions, such as in the presence of triphenylphosphine and diisopropylazodicarboxylate.
  • the reaction is suitably carried out in a polar aprotic solvent (e.g. tetrahydrofuran, in particular anhydrous tetrahydrofuran).
  • LG 4 represents a leaving group such as chloro and LG 5 represents a leaving group such a fluoro.
  • the reaction may be performed in the presence of a strong base such as sodium hydride in a polar aprotic solvent such as DMF.
  • a strong base such as sodium hydride in a polar aprotic solvent such as DMF.
  • the free amine is suitably protected, for example as a carbamate, and Ar is as defined above, and wherein L represents -(CH2)nO(CH 2 )m, as defined above, wherein n is 2 and m is zero by hydroboration with a reagent such as 9-BBN followed by oxidation using hydrogen peroxide in the present of a base such as sodium hydroxide .
  • H represents hydrogen
  • V represents a heteroatom selected from N, NH, O, or S
  • the reaction may, be performed in the presence of a sterically hindered base, for example DIPEA, in an inert solvent, for example dichloromethane.
  • a sterically hindered base for example DIPEA
  • an inert solvent for example dichloromethane
  • LG 6 is defined above for compounds of formula (Ha), and LG 7 is a leaving group, for example a halogen such as chloro.
  • the reaction may, for example be performed in the presence of a sterically hindered base, for example DIPEA, in an inert solvent, for example dichloromethane.
  • a sterically hindered base for example DIPEA
  • DIPEA a sterically hindered base
  • an inert solvent for example dichloromethane
  • R 1 , R 2 , Ar, L, X and R 3 9 are as defined above for compounds of formula (I) and d is an integer 1 to 5 (such as 1 to 4), and an amine R 8 NH 2 using a coupling reagent such as EDC.
  • Compounds of formula (lib) can be synthesisized by reaction of Compound (II) with an isocyanate of formula (lllb) in which Q is N-(CH 2 ) p -C0 2 Et, followed by hydrolysis of the resulting ethyl ester product using, for example, aqueous lithium hydroxide in THF.
  • the reaction may, be performed in the presence of a sterically hindered base, for example DIPEA, in an inert solvent, for example dichloromethane.
  • R 1 , R 2 , Ar, X and R 3 are as defined above for compounds of formula (I) and LG 2 is a leaving group such as 2-isopropenyloxy.
  • Compounds of formula (He) can be synthesized by reaction of Compound (II) with a compound of formula (VI), such as isopropenylchloroformate in the presence of a hindered base such as DIPEA.
  • a compound of formula (VI) such as isopropenylchloroformate
  • DIPEA hindered base
  • the reaction may, be performed in the presence of a sterically hindered base, for example DIPEA, in an inert solvent, for example dichloromethane.
  • a sterically hindered base for example DIPEA
  • an inert solvent for example dichloromethane
  • examples of the disclosure wherein L, R 1 , R 2 , R 3 and Q are as defined above for compounds of formula (I), Ar is naphthyl and X is pyridinyl, may be prepared according to the transformations set out below (Schemes 8a-f). Particular routes disclosed below (Scheme 8b and 8c) provide for examples of compounds of formula (I) wherein NHR or NRR ' represent Q and wherein Q together with NHC(O) forms a urea.
  • examples of the disclosure wherein L, R 1 , R 2 , R 3 and Q are as defined above for compounds of formula (I), Ar is naphthyl and wherein the fragment XNHR 3 represents 2-aminopyrimidinyl or 4-aminopyrimidinyl, may be prepared according to the transformations set out below (Schemes 18a-d). Particular routes disclosed below (Scheme 18c and 18d) provide for examples of compounds of formula (I) wherein NHR or NRR ' represent Q and wherein Q together with NHC(O) forms a urea. Scheme 18a
  • Protecting groups may be required to protect chemically sensitive groups during one or more of the reactions described above, to ensure that the process is efficient. Thus if desired or necessary, intermediate compounds may be protected by the use of conventional protecting groups. Protecting groups and means for their removal are described in "Protective Groups in Organic Synthesis", by Theodora W. Greene and Peter G.M. Wuts, published by John Wiley & Sons Inc; 4 th Rev Ed., 2006, ISBN-10: 0471697540.
  • FCS foetal calf serum
  • RSV respiratory syncytial virus
  • Labels given to intermediates in the examples are independent of labels given to intermediates in other parts of the description.
  • Method 1 Agilent Scalar column C18, 5 ⁇ (4.6 x 50 mm) or Waters XBridge C18, 5 ⁇ (4.6 x 50 mm) flow rate 2.5 mL min "1 eluting with a H 2 0-MeCN gradient containing either 0.1 % v/v formic acid (Method 1 acidic) or NH 3 (Method 1 basic) over 7 min employing UV detection at 215 and 254 nm.
  • Method 2 Agilent Extend C18 column, 1.8 ⁇ (4.6 x 30 mm) at 40°C; flow rate 2.5-4.5 mL.min " 1 eluting with a H 2 0-MeCN gradient containing 0.1 % v/v formic acid over 4 min employing UV detection at 254 nm.
  • Example 7 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - y I oxy ) methy I ) py r i d i n -2 -y I ) -2 -hy d roxy acetam i de :
  • Example 8 yV-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-2-methyl-2-(methylamino)propanamide:
  • Example 12 yV-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-4-methylpiperazine-1 -carboxamide: Intermediate A
  • Example 14 yV-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-3-methoxypropanamide:
  • Example 15 2-(3-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)ureido)-yV-(2-methoxyethyl)acetamide:
  • Example 17 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-3-(methylsulfonyl)propanamide:
  • Example 18 yV-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-3-(methylsulfonyl)-2-oxoimidazolidine-1 -carboxamide:
  • Example 20 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 ⁇ yloxy)methyl)pyridin-2-yl)-2-(methylsulfinyl)acetamide:
  • Example 25 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-2-(2-methoxyethylamino)acetamide:
  • Example 30 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-2-(2-(2-methoxyethoxy)ethylthio)acetamide:
  • Example 32 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl)pyridin-2-yl)-2-(2-morpholinoethylsulfonyl)acetamide:
  • Example 33 2-(Bis(2-methoxyethyl)amino)-yV-(4-((4-(3-(3-ferf-butyl-1 -p-tolyl-1 H-pyrazol- 5-yl)ureido)naphthalen-1 -yloxy)methyl)pyridin-2-yl)acetamide:
  • Example 34 1 -(4-((3-Methylureidopyridin-4-yl)methoxy)naphthalen-1 -yl)-3-(3-ferf-butyl- 1 -p-tolyl-1 H-pyrazol-5-yl)ur
  • Methyl isocyanate (8.5 ⁇ , 0.14 mmol) was added to a solution of Intermediate C (50 mg, 0.10 mmol) in pyridine (1 .0 mL). The reaction mixture was stirred for 2 hr at RT and a further portion of methyl isocyanate (8.5 ⁇ , 0.14 mmol) was added and stirring continued for 72 hr at RT. The solvent was removed in vacuo and the crude product was purified by column chromatography (Si0 2 ,4 g, 10-25% MeOH in DCM, gradient elution). The crude product fractions were combined and triturated with DCM (20 mL).
  • Example 36 W-(4-((4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)methyl) pyridin-3-yl)-2-(2-methoxyethoxy)acetamide:
  • Example 38 W-(4-(2-(4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)ethyl)pyridin-2-yl)-2-(2-methoxyethoxy)acetamide:
  • Example 39 4-(2-(4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - yloxy)ethyl)-1 -methyl -3 -(pyridin-2-yl)urea:
  • Example 40 4-(2-(4-(3-(3-ferf-Butyl-1 -p-tolyl-1 H-pyrazol-5-yl)ureido)naphthalen-1 - y I oxy)ethy I )-3 -(py rid i n -2 -y I )u rea :
  • Methoxyacetyl chloride (17.5 ⁇ , 0.192 mmol) was added dropwise to a solution of Intermediate G (41 mg, 0.077 mmol) and DIPEA (40.1 ⁇ _, 0.230 mmol) in DCM (3 mL) under nitrogen at 0°C. After 15 min the reaction mixture was warmed to RT and was stirred for 1 .5 hr. A solution of NH 3 (1 % in MeOH, 1 .5 mL) was added and stirring continued for a further 2 hr. The reaction mixture was evaporated in vacuo and the residue was subjected to SCX capture and release.
  • a second portion of 3-fe/f-butyl-1 -p-tolyl-1 /-/-pyrazol-5-amine (141 mg, 0.615 mmol) in DCM (1 mL) was processed in a similar manner to the first, by reaction with CDI (100 mg, 0.615 mmol) in DCM (1 mL) and the resulting adduct was then added to the reaction mixture. After a further 2.5 hr the mixture was partitioned between water and DCM. The aqueous layer was extracted with DCM and the combined organic extracts were washed with brine and then dried (MgS0 4 ) and evaporated in vacuo.
  • the mixture was cooled to -78 °C and a further aliquot of the KHMDS solution (36.5 mL, 0.5M in toluene, 18.25 mmol) was added.
  • the mixture was warmed to RT for 10 min and the suspension then re-cooled to -78°C, and a second aliquot of methyl iodide (1 .1 mL, 18.3 mmol) was added.
  • the mixture was warmed to RT and sodium hydride (0.730 g, 18.25 mmol) was added and the mixture stirred at this temperature for 1 hr and then a third aliquot of methyl iodide (1 .1 mL, 18 3mmol) was added.

Abstract

La présente invention concerne entre autres le traitement ou la prévention d'une infection par le virus de la grippe (notamment les sous-types du virus de la grippe A, du virus de la grippe B, de la souche aviaire H5N1, A/H1N1, H3N2 et/ou de la grippe pandémique) à l'aide de composés qui inhibent l'activité de P59-HCK, et un procédé de criblage d'une substance médicamenteuse candidate destinée à prévenir ou à traiter une infection par le virus de la grippe chez un sujet, ledit procédé comportant l'identification d'une substance d'analyse capable d'inhiber l'activité de P59-HCK.
PCT/GB2010/052067 2009-12-11 2010-12-10 Inhibiteurs de kinase de cellules hémopoïétiques (p59-hck) et leur utilisation dans le traitement d'une infection par le virus de la grippe WO2011070369A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/514,644 US20120244120A1 (en) 2009-12-11 2010-12-10 Inhibitors of hemopoietic cell kinase (p59-hck) and their use in the treatment of influenza infection
CN201080063651.5A CN102762204B (zh) 2009-12-11 2010-12-10 造血细胞激酶(p59-hck)的抑制剂及其在流感感染治疗中的用途
AU2010329645A AU2010329645B2 (en) 2009-12-11 2010-12-10 Inhibitors of hemopoietic cell kinase (P59-HCK) and their use in the treatment of influenza infection
JP2012542622A JP2013513596A (ja) 2009-12-11 2010-12-10 造血細胞キナーゼ（ｐ５９−ＨＣＫ）の阻害剤およびインフルエンザ感染の処置におけるそれらの使用
EP10788125.2A EP2509595B1 (fr) 2009-12-11 2010-12-10 Inhibiteurs de kinase de cellules hémopoïétiques (p59-hck) et leur utilisation dans le traitement d'une infection par le virus de la grippe
US14/883,464 US20160045512A1 (en) 2009-12-11 2015-10-14 Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection
US15/706,152 US20180000830A1 (en) 2009-12-11 2017-09-15 Inhibitors of hemopoietic cell kinase (p-59-hck) and their use in the treatment of influenza infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0921730.8 2009-12-11
GBGB0921730.8A GB0921730D0 (en) 2009-12-11 2009-12-11 Method of treatment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,644 A-371-Of-International US20120244120A1 (en) 2009-12-11 2010-12-10 Inhibitors of hemopoietic cell kinase (p59-hck) and their use in the treatment of influenza infection
US14/883,464 Continuation US20160045512A1 (en) 2009-12-11 2015-10-14 Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection

Publications (1)

Publication Number Publication Date
WO2011070369A1 true WO2011070369A1 (fr) 2011-06-16

Family

ID=41666982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/052067 WO2011070369A1 (fr) 2009-12-11 2010-12-10 Inhibiteurs de kinase de cellules hémopoïétiques (p59-hck) et leur utilisation dans le traitement d'une infection par le virus de la grippe

Country Status (7)

Country Link
US (3) US20120244120A1 (fr)
EP (1) EP2509595B1 (fr)
JP (2) JP2013513596A (fr)
CN (1) CN102762204B (fr)
AU (1) AU2010329645B2 (fr)
GB (1) GB0921730D0 (fr)
WO (1) WO2011070369A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158044A2 (fr) 2010-06-17 2011-12-22 Respivert Limited Formulations respiratoires et composés destinés à être utilisés dans ces formulations
WO2013050757A1 (fr) 2011-10-03 2013-04-11 Respivert Limited L-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)naphtalén-1-yl)urées en tant qu'inhibiteurs de p38 map kinase
WO2013050756A1 (fr) 2011-10-03 2013-04-11 Respivert Limited L-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)naphtalèn-1-yl)urées en tant qu'inhibiteurs de p3i map kinase
WO2014076484A1 (fr) 2012-11-16 2014-05-22 Respivert Limited Inhibiteurs de kinase
US8927563B2 (en) 2013-04-02 2015-01-06 Respivert Limited Kinase inhibitor
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
WO2015121444A1 (fr) 2014-02-14 2015-08-20 Respivert Limited Composés hétérocycliques aromatiques utilisés en tant que composés anti-inflammatoires
US9120789B2 (en) 2010-02-01 2015-09-01 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US9155737B2 (en) 2007-12-19 2015-10-13 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-B]pyrazin-8-substituted compounds and their use
US9242960B2 (en) 2009-04-03 2016-01-26 Respivert, Ltd. P38MAP kinase inhibitors
US9249125B2 (en) 2012-08-29 2016-02-02 Respivert Limited Pyrazole derivatives as p38 MAP inhibitors
US9260410B2 (en) 2010-04-08 2016-02-16 Respivert Ltd. P38 MAP kinase inhibitors
US9499486B2 (en) 2014-10-01 2016-11-22 Respivert Limited Kinase inhibitor
US9701670B2 (en) 2012-08-17 2017-07-11 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
US9708317B2 (en) 2013-11-25 2017-07-18 Cancer Research Technology Limited Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-B]pyrazin-3-one derivatives
US9725447B2 (en) 2013-11-25 2017-08-08 Cancer Research Technology Limited 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
US9790209B2 (en) 2012-08-29 2017-10-17 Respivert Limited Kinase inhibitors
US9796742B2 (en) 2012-08-29 2017-10-24 Respivert Limited Kinase inhibitors
US9850233B2 (en) 2013-03-14 2017-12-26 Respivert Limited Kinase inhibitors
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
US10072034B2 (en) 2016-04-06 2018-09-11 Respivert Limited Kinase inhibitors
WO2021013712A1 (fr) 2019-07-19 2021-01-28 Anagenesis Biotechnologies S.A.S. Dérivés d'urée polyaromatiques et leur utilisation dans le traitement de maladies musculaires
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
CN115181736B (zh) * 2022-01-07 2023-05-30 中国科学院海洋研究所 一种可以结合脂多糖的蛋白酶pck及其制备和应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043384A1 (fr) 1999-01-19 2000-07-27 Boehringer Ingelheim Pharmaceuticals, Inc. Composes heterocycliques aromatiques utilises comme agents anti-inflammatoires
US20040009173A1 (en) * 2002-07-10 2004-01-15 Annabelle Friera Modulators of leukocyte activation, Hck compositions and methods of use
WO2006136562A1 (fr) 2005-06-20 2006-12-28 Tibotec Pharmaceuticals Ltd Benzimidazoles substitués par un hétérocyclylaminoalkyle
WO2007087448A1 (fr) 2006-01-30 2007-08-02 Irm Llc Dérivés d'imadazole spiro utilisés comme modulateurs du récepteur ppar
WO2007089512A1 (fr) 2006-01-27 2007-08-09 Array Biopharma Inc. Activateurs de glucokinases
WO2007096764A2 (fr) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
WO2008157518A1 (fr) * 2007-06-15 2008-12-24 Drake Richard R Biomarqueurs d'une réponse à un vaccin de la grippe
WO2010038086A2 (fr) * 2008-10-02 2010-04-08 Respivert Limited Nouveaux composés
WO2010038085A2 (fr) * 2008-10-02 2010-04-08 Respivert Limited Inhibiteur de la p38 mapk kinase
WO2010067131A1 (fr) * 2008-12-11 2010-06-17 Respivert Limited Inhibiteur de kinase map p38
WO2010112936A1 (fr) * 2009-04-03 2010-10-07 Respivert Limited Inhibiteur de la p38map kinase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006318428A1 (en) * 2005-11-23 2007-05-31 Intermune, Inc. Method of modulating stress-activated protein kinase system

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043384A1 (fr) 1999-01-19 2000-07-27 Boehringer Ingelheim Pharmaceuticals, Inc. Composes heterocycliques aromatiques utilises comme agents anti-inflammatoires
US20040009173A1 (en) * 2002-07-10 2004-01-15 Annabelle Friera Modulators of leukocyte activation, Hck compositions and methods of use
WO2006136562A1 (fr) 2005-06-20 2006-12-28 Tibotec Pharmaceuticals Ltd Benzimidazoles substitués par un hétérocyclylaminoalkyle
WO2007089512A1 (fr) 2006-01-27 2007-08-09 Array Biopharma Inc. Activateurs de glucokinases
WO2007087448A1 (fr) 2006-01-30 2007-08-02 Irm Llc Dérivés d'imadazole spiro utilisés comme modulateurs du récepteur ppar
WO2007096764A2 (fr) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
WO2008157518A1 (fr) * 2007-06-15 2008-12-24 Drake Richard R Biomarqueurs d'une réponse à un vaccin de la grippe
WO2010038086A2 (fr) * 2008-10-02 2010-04-08 Respivert Limited Nouveaux composés
WO2010038085A2 (fr) * 2008-10-02 2010-04-08 Respivert Limited Inhibiteur de la p38 mapk kinase
WO2010067131A1 (fr) * 2008-12-11 2010-06-17 Respivert Limited Inhibiteur de kinase map p38
WO2010112936A1 (fr) * 2009-04-03 2010-10-07 Respivert Limited Inhibiteur de la p38map kinase

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Centers for Disease and Prevention (CDC)", MORB. MORTAL. WKLY. REP., vol. 58, 2009, pages 433 - 435
"Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS INC
AOKI F.Y. ET AL., ANTIVIR. THER., vol. 12, 2007, pages 603 - 16
BARRY J.M.: "Workshop Summary", 2005, THE NATIONAL ACADEMIES PRESS, pages: 60 - 61
CHANG Y -J ET AL: "Interferon-[gamma]-induced epithelial ICAM-1 expression and monocyte adhesion. Involvement of protein kinase c-dependent c-Src tyrosine kinase activation pathway", JOURNAL OF BIOLOGICAL CHEMISTRY 20020301 US LNKD- DOI:10.1074/JBC.M109924200, vol. 277, no. 9, 1 March 2002 (2002-03-01), pages 7118 - 7126, XP002265665, ISSN: 0021-9258 *
DUFAU I ET AL: "Optimization of a homogeneous assay for kinase inhibitors in plant extracts", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 6, 1 January 2008 (2008-01-01), pages 673 - 682, XP007917594, ISSN: 1540-658X, [retrieved on 20081127], DOI: DOI:10.1089/ADT.2008.143 *
GUBAREVA L.V. ET AL., LANCET, vol. 355, 2000, pages 827 - 35
GUIET R.; POINCLOUX R. ET AL., EUR. J. CELL BIOL., vol. 87, 2008, pages 527 - 42
NGUYEN J.T. ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 53, 2009, pages 4115 - 4126
NICHOL K.L. ET AL., N. ENGL. J. MED., vol. 333, 1995, pages 889 - 93
REGAN, J. ET AL., J. MED. CHEM., vol. 46, 2003, pages 4676 - 4686
SIMONSEN L. ET AL., J. INFECT. DIS., vol. 178, 1998, pages 53 - 60
SU L ET AL: "Distinct mechanisms of STAT phosphorylation via the interferon-[alpha]/[beta] receptor. Selective inhibition of STAT3 and STAT5 by piceatannol", JOURNAL OF BIOLOGICAL CHEMISTRY 20000428 US LNKD- DOI:10.1074/JBC.275.17.12661, vol. 275, no. 17, 28 April 2000 (2000-04-28), pages 12661 - 12666, XP009143824, ISSN: 0021-9258 *
WANG B. ET AL., ANTIVIRAL. RES., vol. 87, 2010, pages 16 - 21

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540372B2 (en) 2007-12-19 2017-01-10 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
US9155737B2 (en) 2007-12-19 2015-10-13 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-B]pyrazin-8-substituted compounds and their use
US9242960B2 (en) 2009-04-03 2016-01-26 Respivert, Ltd. P38MAP kinase inhibitors
US9820976B2 (en) 2010-02-01 2017-11-21 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US9439893B2 (en) 2010-02-01 2016-09-13 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US9120789B2 (en) 2010-02-01 2015-09-01 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
US10144721B2 (en) 2010-04-08 2018-12-04 Respivert Ltd. P38 MAP kinase inhibitors
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
US9260410B2 (en) 2010-04-08 2016-02-16 Respivert Ltd. P38 MAP kinase inhibitors
WO2011158044A2 (fr) 2010-06-17 2011-12-22 Respivert Limited Formulations respiratoires et composés destinés à être utilisés dans ces formulations
US10738032B2 (en) 2011-10-03 2020-08-11 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors
US10238658B2 (en) 2011-10-03 2019-03-26 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
WO2013050757A1 (fr) 2011-10-03 2013-04-11 Respivert Limited L-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)naphtalén-1-yl)urées en tant qu'inhibiteurs de p38 map kinase
US9108950B2 (en) 2011-10-03 2015-08-18 Respivert, Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
US9850231B2 (en) 2011-10-03 2017-12-26 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
US9475796B2 (en) 2011-10-03 2016-10-25 Respivert Limited 1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
US10813932B2 (en) 2011-10-03 2020-10-27 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
US10266519B2 (en) 2011-10-03 2019-04-23 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors
US9993478B2 (en) 2011-10-03 2018-06-12 Respivert, Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
US9724347B2 (en) 2011-10-03 2017-08-08 Respivert, Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors
WO2013050756A1 (fr) 2011-10-03 2013-04-11 Respivert Limited L-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)naphtalèn-1-yl)urées en tant qu'inhibiteurs de p3i map kinase
US9701670B2 (en) 2012-08-17 2017-07-11 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
US9249125B2 (en) 2012-08-29 2016-02-02 Respivert Limited Pyrazole derivatives as p38 MAP inhibitors
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
US9796742B2 (en) 2012-08-29 2017-10-24 Respivert Limited Kinase inhibitors
US9790209B2 (en) 2012-08-29 2017-10-17 Respivert Limited Kinase inhibitors
WO2014076484A1 (fr) 2012-11-16 2014-05-22 Respivert Limited Inhibiteurs de kinase
US9732063B2 (en) 2012-11-16 2017-08-15 Respivert Limited Kinase inhibitors
US10301288B2 (en) 2013-03-14 2019-05-28 Topivert Pharma Limited Kinase inhibitors
US9850233B2 (en) 2013-03-14 2017-12-26 Respivert Limited Kinase inhibitors
US9481648B2 (en) 2013-04-02 2016-11-01 Respivert Limited Kinase inhibitors
US9790174B2 (en) 2013-04-02 2017-10-17 Respivert Limited Kinase inhibitors
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
US8927563B2 (en) 2013-04-02 2015-01-06 Respivert Limited Kinase inhibitor
US10435361B2 (en) 2013-04-02 2019-10-08 Topivert Pharma Limited Kinase inhibitors
US10100053B2 (en) 2013-11-25 2018-10-16 Cancer Research Technology Limited Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives
US9725447B2 (en) 2013-11-25 2017-08-08 Cancer Research Technology Limited 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
US10167282B2 (en) 2013-11-25 2019-01-01 Cancer Research Technology Limited 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
US9708317B2 (en) 2013-11-25 2017-07-18 Cancer Research Technology Limited Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-B]pyrazin-3-one derivatives
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
EP3357919A1 (fr) 2014-02-14 2018-08-08 Respivert Limited Composés hétérocycliques aromatiques utilisés en tant que composés anti-inflammatoires
US9884845B2 (en) 2014-02-14 2018-02-06 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
US11634406B2 (en) 2014-02-14 2023-04-25 Respivert Ltd. Inhibitor of p38 MAP kinase
US10045980B2 (en) 2014-02-14 2018-08-14 Respivert Ltd Inhibitor of p38 map kinase
EP3418279A1 (fr) 2014-02-14 2018-12-26 Respivert Limited Composés hétérocycliques aromatiques utilisés en tant que composés anti-inflammatoires
US11142515B2 (en) 2014-02-14 2021-10-12 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
US9624196B2 (en) 2014-02-14 2017-04-18 Respivert Ltd. Inhibitor of p38 MAP kinase
US10815217B2 (en) 2014-02-14 2020-10-27 Respivert Ltd. Inhibitor of p38 MAP kinase
US10294216B2 (en) 2014-02-14 2019-05-21 Respivert Limited Pyrazolyl ureas as kinase inhibitors
US9447076B2 (en) 2014-02-14 2016-09-20 Respivert Ltd. Inhibitor of p38 map kinase
WO2015121444A1 (fr) 2014-02-14 2015-08-20 Respivert Limited Composés hétérocycliques aromatiques utilisés en tant que composés anti-inflammatoires
US10392346B2 (en) 2014-10-01 2019-08-27 Topivert Pharma Limited Kinase inhibitors
US9499486B2 (en) 2014-10-01 2016-11-22 Respivert Limited Kinase inhibitor
US9751837B2 (en) 2014-10-01 2017-09-05 Respivert Limited Kinase inhibitors
US10941115B2 (en) 2014-10-01 2021-03-09 Oxular Acquisitions Limited Kinase inhibitors
US9822076B2 (en) 2014-10-01 2017-11-21 Respivert Limited Kinase inhibitor
US10125100B2 (en) 2014-10-01 2018-11-13 Respivert Limited Kinase inhibitors
US10072034B2 (en) 2016-04-06 2018-09-11 Respivert Limited Kinase inhibitors
US10442828B2 (en) 2016-04-06 2019-10-15 Topivert Pharma Limited Kinase inhibitors
WO2021013712A1 (fr) 2019-07-19 2021-01-28 Anagenesis Biotechnologies S.A.S. Dérivés d'urée polyaromatiques et leur utilisation dans le traitement de maladies musculaires
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites

Also Published As

Publication number Publication date
AU2010329645B2 (en) 2015-05-28
JP2016128489A (ja) 2016-07-14
CN102762204B (zh) 2014-11-19
GB0921730D0 (en) 2010-01-27
EP2509595B1 (fr) 2018-04-11
US20160045512A1 (en) 2016-02-18
CN102762204A (zh) 2012-10-31
JP2013513596A (ja) 2013-04-22
US20180000830A1 (en) 2018-01-04
JP6247709B2 (ja) 2017-12-13
AU2010329645A1 (en) 2012-06-07
EP2509595A1 (fr) 2012-10-17
US20120244120A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
EP2509595B1 (fr) Inhibiteurs de kinase de cellules hémopoïétiques (p59-hck) et leur utilisation dans le traitement d'une infection par le virus de la grippe
WO2011070368A1 (fr) Utilisation antivirale de composés d'urée
US8299073B2 (en) P38 MAP kinase inhibitors
AU2010231120B2 (en) p38 MAP kinase inhibitor
AU2011266797B2 (en) Methods
EP2582432A1 (fr) Dérivés d'uréido-pyrazole destinés à être utilisés dans le traitement d'infections par un rhinovirus
EP2556065A1 (fr) Inhibiteurs de la map kinase p38 à base de pyrazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080063651.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788125

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010329645

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010788125

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010329645

Country of ref document: AU

Date of ref document: 20101210

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012542622

Country of ref document: JP

Ref document number: 13514644

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1683/MUMNP/2012

Country of ref document: IN